23133-37-1

Usage

Uses

Used in Pharmaceutical Industry:
1-Propyl-4-piperidone is used as an intermediate in the synthesis of various pharmaceutical compounds. Its application is particularly significant in the preparation of 9-[2-(2-methyl-5-pyridyl)-ethyl]-3-propyl-1,2,3,4-tetrahydro-γ-carboline, which is a compound with potential therapeutic properties.
Used in Chemical Synthesis:
Due to its unique chemical structure, 1-Propyl-4-piperidone serves as a valuable building block in the synthesis of a wide range of organic compounds. It can be utilized in the development of new molecules with specific applications in various fields, such as materials science, agrochemicals, and specialty chemicals.
Used in Research and Development:
1-Propyl-4-piperidone is also used as a research compound for studying its chemical properties and potential applications. It can be employed in academic and industrial research to explore new reactions, mechanisms, and the development of novel chemical processes.

InChI:InChI=1/C8H15NO/c1-2-5-9-6-3-8(10)4-7-9/h2-7H2,1H3/p+1

Upstream product

• 41661-47-6 piperidin-4-one 
• 106-94-5 propyl bromide 
• 41979-39-9 4-piperidone hydrochloride 
• 107-08-4 1-iodo-propane 

Downstream Products

• 72808-65-2 5-methoxy-3-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole 
• 861968-00-5 (3E,5E)-3,5-bis(4-hydroxybenzylidene)-1-propylpiperidin-4-one 
• 861968-04-9 (3E,5E)-3,5-bis(4-hydroxy-3-methoxybenzylidene)-1-propylpiperidin-4-one 
• 488100-05-6 C₂₃H₂₆FN₃O 
• 229479-46-3 N-(3-methoxyphenyl)-1-propyl-4-piperidinamine 
• 882737-41-9 4-hydroxy-4-(3-(methylthio)phenyl)-1-propylpiperidin-1-ium chloride 
• 683271-61-6 N-benzyl-1-propyl-4-piperidinamine 
• 683271-37-6 N,N-Diethyl-4-[benzyl(1-propylpiperidin-4-yl)amino]benzamide 
• 1078691-72-1 (2-amino-6-n-propyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)(3,4,5-trimethoxyphenyl)methanone 
• 340812-23-9 C₁₄H₁₉N₅S 

Relevant academic research and scientific papers

Effect of cathepsin K inhibitors on bone resorption

On the basis of the pyrrolopyrimidine core structure that was previously discovered, cathepsin K inhibitors having a spiro amine at the P3 have been explored to enhance the target, bone marrow, tissue distribution. Several spiro structures were identified with improved distribution toward bone marrow. The representative inhibitor 7 of this series revealed in vivo reduction in C-terminal telopeptide of type I collagen in rats and monkeys.

Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation

We previously discovered and validated a class of piperidinyl ureas that regulate defective in cullin neddylation 1 (DCN1)-dependent neddylation of cullins. Here, we report preliminary structure-activity relationship studies aimed at advancing our high-throughput screen hit into a tractable tool compound for dissecting the effects of acute DCN1-UBE2M inhibition on the NEDD8/cullin pathway. Structure-enabled optimization led to a 100-fold increase in biochemical potency and modestly increased solubility and permeability as compared to our initial hit. The optimized compounds inhibit the DCN1-UBE2M protein-protein interaction in our TR-FRET binding assay and inhibit cullin neddylation in our pulse-chase NEDD8 transfer assay. The optimized compounds bind to DCN1 and selectively reduce steady-state levels of neddylated CUL1 and CUL3 in a squamous cell carcinoma cell line. Ultimately, we anticipate that these studies will identify early lead compounds for clinical development for the treatment of lung squamous cell carcinomas and other cancers.

Novel Carboline Derivatives as Potent Antifungal Lead Compounds: Design, Synthesis, and Biological Evaluation

A series of novel antifungal carboline derivatives was designed and synthesized, which showed broad-spectrum antifungal activity. Particularly, compound C38 showed comparable in vitro antifungal activity to fluconazole without toxicity to human embryonic lung cells. It also exhibited good fungicidal activity against both fluconazole-sensitive and -resistant Candida albicans cells and had potent inhibition activity against Candida albicans biofilm formation and hyphal growth. Moreover, C38 showed good synergistic antifungal activity in combination with fluconazole (FLC) against FLC-resistant Candida species. Preliminary mechanism studies revealed that C38 might act by inhibiting the synthesis of fungal cell wall.

Lightening Agents and/or Dyes that Contain Aldehyde(s)

Agents for dyeing and/or lightening keratin fibers, in particular human hair, containing, relative to the weight thereof, 0.001 to 15 wt. % of at least one aldehyde of the formula (I): wherein X represents —CH(R2)—SO2—Y—R1, —CR3R4R5, or wherein Y represents —CH(CHO)— or —CH2— or a chemical bond, and wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 independently represents —H or —CN or —F or —Cl or —Br or —I or —CHO or —NH2 or —NO2 or —CF3 or —CCl3 or —CF2CF3 or —CCl2CCl3 or an optionally substituted (C1-C6) alkyl group or a hydroxyalkyl group or a polyhydroxyalkyl group or an optionally substituted (C1-C6) alkylene group, and wherein the agent contains no oxidation dye precursors of developer and coupler type.

Design and synthesis of rho kinase inhibitors (III)

The structure-activity relationship of Rho kinase inhibitors bearing an isoquinoline scaffold was studied. N-(1-Benzyl-3-pyrrolidyl)-N-(5-isoquinolyl)amine analogues were optimized with respect to their inhibitory potencies for the enzyme and for chemotaxis. The potent analogues were further evaluated by an ex vivo test in which the selected compounds were orally administered to rats, and the Rho kinase inhibitory potency observed in the rat serum was evaluated 3 h after the administration. Compound 23g showed a high level of Rho kinase inhibitory activity in the rat serum and was stable in an in vitro metabolic test using a microsomal cytochrome preparation. The (R)-isomer of 23g displayed a higher level of inhibitory potency than the (S)-isomer in a cell-free kinase assay and in the cell migration assay (IC50ENZ = 25 nM and IC50MCP = 1 μ M). The (R)-isomer successfully inhibited the phosphorylation of MBS (myosin-binding subunit) in cells.

Design and synthesis of Rho kinase inhibitors (I)

Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure-activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide.

N-Heterocyclic-9-xanthenylamines

The compounds are N-piperidinyl and pyrrolidinyl-9-xanthenylamines which are inhibitors of gastric acid secretion.